Minerva Neurosciences (FRA:4MNA) ROCE % : -50.02% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Minerva Neurosciences ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Minerva Neurosciences's annualized ROCE % for the quarter that ended in Mar. 2024 was -50.02%.

Minerva Neurosciences ROCE % Historical Data

The historical data trend for Minerva Neurosciences's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Minerva Neurosciences ROCE % Chart

Minerva Neurosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-74.66

2.94

-72.67

-40.05

-39.91

Minerva Neurosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
ROCE %	Get a 7-Day Free Trial															-38.64	-28.98	-37.00	-47.68	-50.02

Minerva Neurosciences ROCE % Calculation

Minerva Neurosciences's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-19.919	/	( ( (52.002 - 1.301)	+	(52.177 - 3.063) )	/ 2 )
	=	-19.919	/	( (50.701	+	49.114)	/ 2 )
	=	-19.919	/	49.9075
	=	-39.91 %

Minerva Neurosciences's ROCE % of for the quarter that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2024 )		(Q: Dec. 2023 )		(Q: Mar. 2024 )
	=	-23.252	/	( ( (52.177 - 3.063)	+	(46.469 - 2.605) )	/ 2 )
	=	-23.252	/	( ( 49.114	+	43.864 )	/ 2 )
	=	-23.252	/	46.489
	=	-50.02 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

Minerva Neurosciences (FRA:4MNA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Minerva Neurosciences ROCE % Related Terms

Thank you for viewing the detailed overview of Minerva Neurosciences's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Minerva Neurosciences (FRA:4MNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Minerva Neurosciences Inc (FRA:4MNA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

NERV:USA 4MNA:Germany

Address

1500 District Avenue, Burlington, MA, USA, 01803

Website

https://www.minervaneurosciences.com

Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It primarily focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, major depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and major depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.

Minerva Neurosciences (FRA:4MNA) Headlines

No Headlines